ClinicalTrials.gg
Active, not recruitingNCT05044910TBMAMUpdated May 29, 2024

The Impact of Malnutrition on Immune Responses to Tuberculosis

An observational study in Malnutrition, Child and Tuberculosis, sponsored by Tuberculosis Research Centre, India. Active, not recruiting at 2 sites in India. Open to participants aged 12 Months to 60 Months. Per ClinicalTrials.gov, last updated 2024-05-29.

Sponsored by Tuberculosis Research Centre, India · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 2 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
12 Months to 60 Months
Sex
All
01

Study summary

The aim of this study is to assess immune responses to Mtb in children with MAM compared to well-nourished children and to evaluate the impact of a nutrition intervention on these immune responses.

Read the detailed description

Immune dysfunction in malnourished children is poorly characterised. The aim of this study is to assess immune responses to Mycobacterium tuberculosis (Mtb) in children with moderate acute malnutrition (MAM) compared to wellnourished children and to evaluate the impact of a nutrition intervention on these immune responses. Innate and adaptive immune responses to Mtb will be characterised in four groups: 1) MAM children with TB disease; 2) Wellnourished children with TB disease; 3) MAM children with latent TB infection; 4) Well-nourished children with latent TB infection. A range of assays to compare innate, adaptive and functional immune responses to TB between groups will be performed. Whether nutritional supplementation improves immune function in MAM children remains uncertain. Hence, children in all four groups will be followed up during 6 months of TB therapy/chemoprophylaxis. MAM children will receive 12 weeks of concomitant ready-to-use supplementary food, to evaluate longitudinal changes in innate and adaptive immune function, monocyte:lymphocyte ratio and mycobacterial growth inhibition. The results of this study will provide data to understand the reasons for infection susceptibility in malnourished children and provide a proof-of-concept that nutritional rehabilitation promotes immune rehabilitation. It will also provide a proof-of concept for use of nutritional supplementation as adjust therapy in TB disease

02

Conditions studied

  • Malnutrition, Child
  • Tuberculosis

Keywords

  • malnutrition
  • moderate acute malnutrition
  • immunology
03

In context

Child Nutrition Disorders

168 studies on the registry are indexed under Child Nutrition Disorders; 34 are open to participants now.

This study's planned enrollment of 200 is below the median of 300 across 32 observational studies indexed under Child Nutrition Disorders.

Browse Child Nutrition Disorders studies →

Lead sponsor

Tuberculosis Research Centre, India is the lead sponsor of 15 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Months to 60 Months
Sexes eligible
All
Sampling method
Non-probability sample

Study population

HIV negative, BCG vaccinated

Eligibility criteria

Inclusion Criteria:

  • Age 12-60 months
  • -negative
  • BCG vaccinated
  • Moderate acute malnutrition (WHZ -2 to -3 or MUAC 115 - 125mm ± HAZ \<-2)
  • TB disease
  • Latent TB infection

Exclusion Criteria:

  • Inclusion criteria not met
  • Severe acute malnutrition (WHZ\<-3; MUAC\<115mm; bilateral oedema)
  • Severe anaemia (: \<7g/dl)
  • Chronic infection (HIV, or C)
  • Chronic disease (e.g. Crohn's disease)
  • Feeding problems (eg cerebral palsy) that prevent ingestion of RUSF
  • Known nut allergy
  • MDR TB disease and contacts of MDR TB adults
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • MAM children with TB disease

    Dietary Supplement: Ready to Use supplementary food (RUSF)

  • Wellnourished children with TB disease
  • MAM children with latent TB infection

    Dietary Supplement: Ready to Use supplementary food (RUSF)

  • Well-nourished children with latent TB infection

Interventions

  • Dietary supplementReady to Use supplementary food (RUSF)

    Children with malnutrition will be given RUSF

06

What researchers measure

Primary outcomes

  1. IFNγ concentration

    IFNγ concentration in supernatant after overnight incubation of whole blood with TB antigens

    Time frame: 6 months

07

Study locations

2 sites
  • Institute of Child Health
    Chennai, Tamil Nadu 600 008, India
  • Government Stanley Medical College and Hospital
    Chennai, Tamil Nadu 600001, India
08

References and documents

Individual participant data

Plan to share: No — Data will be shared according to ICMR rules and regulations after appropriate approvals

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2020 (actual). Primary completion is estimated for Aug 2024, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2021
First posted
Sep 16, 2021
StartActual
Aug 1, 2020
Primary completionEst.
Aug 31, 2024
CompletionEst.
Dec 1, 2024
Last update
May 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05044910
Lead sponsor
Tuberculosis Research Centre, India
Collaborators
Institute of Child Health, Madras Medical College, Chennai, Stanley Medical College, Kanchi Kamakoti Childs Trust Hospital, Chennai, India, Queen Mary University of London, London School of Hygiene and Tropical Medicine, DBT, India
Responsible party
Sponsor
First posted
Sep 16, 2021
Start date
Aug 1, 2020
Primary completion
Aug 31, 2024 (estimated)
Completion
Dec 1, 2024 (estimated)
Last update
May 29, 2024

Study contacts

Aishwarya Venkataraman, MRCPCH
principal investigator · ICMR-NIRT

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion